Turning patient symptoms into computable signal.
REPROSENT captures the day-to-day treatment experience and makes it usable for dose, safety, and development decisions.
We deploy as an observational overlay on top of existing trials and care programs – EHR-agnostic, non-interventional, and aligned with current safety reporting – so teams can finally see how patients are actually living on therapy.
Infrastructure for real-time human response
REPROSENT sits alongside existing systems as a lightweight data engine – capturing patient experience, aligning it with dose and timing, and returning a clean signal that development and clinical teams can act on.
Patient-side capture
Patients (or caregivers) complete a 1–2 minute check-in from home, describing their actual experience in plain language mapped to structured scales.
Clinician context
Treating teams review concise views in-flow, confirm grading where needed, and keep standard AE and safety workflows unchanged.
Computable dataset
The platform turns this stream into longitudinal, dose-aware, AI-ready data that can be reused across trials, programs, and models.
Advanced therapies without advanced tolerability data
Antibody–drug conjugates, immunotherapies, and other next-generation agents can be life-extending – but they also create complex, day-to-day toxicities that are largely invisible between visits.
Blind spots between visits
Most oncology programs still rely on intermittent clinic check-ins and retrospective recall, missing how symptoms evolve in real life.
Dose and safety decisions
Without high-resolution tolerability data, teams are forced to make dose, schedule, and escalation decisions using partial information.
Future-proofing development
Regulators and medical teams are asking for stronger evidence on how patients actually live on therapy. A reusable human-signal layer makes that feasible.
Built for the teams advancing cancer therapy
REPROSENT works with organizations that need higher-fidelity tolerability signal without slowing development or changing core systems.
Biopharma development & medical teams
- Early-phase and registrational trials needing clearer exposure-tolerability insight.
- On-market programs focused on adherence, persistence, and real-world use.
- Medical and HEOR teams building evidence for optimized dosing and supportive care.
Cooperative groups & cancer centers
- Multi-site networks standardizing how patient experience is captured and compared.
- Academic and community centers needing an EHR-agnostic tolerability layer.
- Partners exploring new metrics, digital biomarkers, and AI models grounded in human response.
Get in touch
If you’re exploring dose optimization, tolerability signal, or patient-centric models in oncology, we’d be glad to connect.